Skip to main content
. Author manuscript; available in PMC: 2013 Mar 11.
Published in final edited form as: Gynecol Oncol. 2008 May 21;110(2):196–201. doi: 10.1016/j.ygyno.2008.04.002

Table 1.

Serum levels of tumor markers among endometrial cancer patients and healthy individuals.

Tumor Marker Controls (N = 156) Median (range) Stage I Cancer (N = 122) Median (range) P value* All Cancer Stages (N = 171) Median (range) P value*
CA125 (U/ml) 11.2 (3.3 – 73.6) 14.5 (3.0 – 432.9) 0.0001 16.6 (3.0 - 1,426.6) <0.0001
HE4 (pM) 35.4 (18.0 - 127.8) 60.5 (1.1 – 1022.1) <0.0001 71.5 (1.1 - 4,062.7) <0.0001
CA72.4 (U/ml) 1.6 (0.9 - 24.4) 1.8 (0.9 - 280.3) 0.7927 1.9 (0.9 - 280.3) 0.1172
Serum SMRP (nM) 0.6 (0.1 - 2.2) 0.6 (0.0 - 13.3) 0.6053 0.6 (0.0 - 13.3) 0.8664
*

Wilcoxon rank sum (Mann-Whitney) test p-values for comparison of controls vs. cancer patients